Zobrazeno 1 - 10
of 195
pro vyhledávání: '"Catherine, Sebban"'
Autor:
David Sibon, Franck Morschhauser, Matthieu Resche-Rigon, David Ghez, Jehan Dupuis, Ambroise Marçais, Bénédicte Deau-Fischer, Reda Bouabdallah, Catherine Sebban, Gilles Salles, Pauline Brice
Publikováno v:
Haematologica, Vol 101, Iss 4 (2016)
We assessed the long-term results of autologous stem-cell transplantation for patients with first-relapsed or refractory Hodgkin lymphoma included in the prospective Lymphoma Study Association/Société Française de Greffe de Moelle H96 trial. This
Externí odkaz:
https://doaj.org/article/b50645cc6a2e45c0920c619cc4190170
Autor:
Julie Abraham, Marc Simon, Hervé Tilly, Josette Brière, Anne-Ségolène Cottereau, Lucie Oberic, Michel Meignan, Olivier Casasnovas, Olivier Fitoussi, Pascal Godmer, Christophe Fruchart, Laurence Sanhes, Laetitia Vercellino, Gian Matteo Pica, Pierre Feugier, Gilles Salles, Vincent Ribrag, Catherine Thieblemont, Armando López-Guillermo, Judith Trotman, Bernadette Corront, Loïc Chartier, Hugo Gonzalez, Franck Morschhauser, Philippe Gaulard, Bachra Choufi, Catherine Sebban, L. Roulin, Reda Bouabdallah, Sylvia Snauwaert
Publikováno v:
Blood. 135:1396-1405
Early identification of ultra-risk diffuse large B-cell lymphoma (DLBCL) patients is needed to aid stratification to innovative treatment. Previous studies suggested high baseline total metabolic tumor volume (TMTV) negatively impacts survival of DLB
Autor:
Amine Belhabri, Muriel Rogasik, Mohamad Sobh, Catherine Chassagne-Clément, Yves Bertrand, Gilles Salles, Bruno Anglaret, Anne-Sophie Michallet, Catherine Sebban, Selim Corm, Françoise Berger, Claire Freycon, Pascale Cony-Makhoul, Isabelle Ray-Coquard, Pierre Faurie, Jérôme Cornillon, Arthur Dony
Publikováno v:
Journal of Adolescent and Young Adult Oncology. 8:684-696
Background: Management of adolescent and young adults (AYAs) cancer is very heterogeneous. In the case of lymphomas, outcomes are mostly favorable but there is still room for improvement. Design: W...
Autor:
Umberto Vitolo, Qian Shi, Jesse G. Dixon, Emmanuel Gyan, Carla Casulo, Jennifer Le-Rademacher, Catherine Sebban, Eva Kimby, Gilles Salles, Kenneth A. Foon, Michael Herold, Wolfgang Hiddemann, Tina Nielsen, Eva Hoster, Christopher R. Flowers, Howard S. Hochster, Robert Marcus
Publikováno v:
Blood
Observational studies and stand-alone trials indicate that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy (POD24), have poor outcomes. We performed a pooled analysis of 13 r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9f853e3cbd32f051cb18f8dd4b5fe2c
https://europepmc.org/articles/PMC9974165/
https://europepmc.org/articles/PMC9974165/
Autor:
Marie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, Cyrille Hulin, Gerald Marit, Xavier Leleu, Lionel Karlin, Murielle Roussel, Anne-Marie Stoppa, Francois Guilhot, Thierry Lamy, Laurent Garderet, Brigitte Pegourie, Mamoun Dib, Catherine Sebban, Pascal Lenain, Sabine Brechignac, Bruno Royer, Marc Wetterwald, Laurence Legros, Frédérique Orsini-Piocelle, Laurent Voillat, Xavier Delbrel, Denis Caillot, Margaret Macro, Thierry Facon, Michel Attal, Philippe Moreau, Hervé Avet-Loiseau, Jill Corre
Publikováno v:
Haematologica, Vol 99, Iss 7 (2014)
Age is a strong prognostic factor in multiple myeloma. The overall survival is shorter in patients older than 66 years, and even shorter in those older than 75 years. Whether age is also a prognostic parameter in patients younger than 66 years treate
Externí odkaz:
https://doaj.org/article/ff04f2e7a23f40eea36e5e25ccae401d
Autor:
Nicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, Danièle Canioni, Catherine Sebban, René-Olivier Casasnovas, Richard Delarue, Anne Sonet, Pauline Beaussart, Tony Petrella, Sylvie Castaigne, Serge Bologna, Gilles Salles, Alain Rahmouni, Philippe Gaulard, Corinne Haioun
Publikováno v:
Haematologica, Vol 98, Iss 11 (2013)
A previous pilot study with rituximab, gemcitabine and oxaliplatin showed promising activity in patients with refractory/relapsed B-cell lymphoma. We, therefore, conducted a phase II study to determine whether these results could be reproduced in a m
Externí odkaz:
https://doaj.org/article/054a821271f04e3b922eb8f262a1b18d
Autor:
Emmanuel Bachy, Roch Houot, Franck Morschhauser, Anne Sonet, Pauline Brice, Karim Belhadj, Guillaume Cartron, Bruno Audhuy, Christophe Fermé, Pierre Feugier, Catherine Sebban, Vincent Delwail, Hervé Maisonneuve, Steven Le Gouill, Sophie Lefort, Nicole Brousse, Charles Foussard, Gilles Salles
Publikováno v:
Haematologica, Vol 98, Iss 7 (2013)
Anti-CD20-containing chemotherapy regimens have become the standard of care for patients with follicular lymphoma needing cytotoxic therapy. Four randomized trials demonstrated a clinical benefit for patients treated with rituximab. However, no long-
Externí odkaz:
https://doaj.org/article/125284c7cad047e385844055a7af268b
Autor:
André Garrel, Vanina Oliveri, Hervé Tilly, Gandhi Damaj, Sabine Anthony, Franck Morschhauser, Rene-Olivier Casasnovas, Florence Broussais, Loic Ysebaert, Catherine Thieblemont, Richard Delarue, Nicolas Mounier, Michel Henry-Amar, Virginie Nerich, Jean-Philippe Jais, Vincent Ribrag, Pierre Feugier, Gilles Salles, Corinne Haioun, Catherine Sebban, Pierre Hebel
Publikováno v:
Bulletin du Cancer. 104:221-231
Since the introduction of targeted therapies, specific lymphoma mortality has decreased. Possible long-term toxicities, however, are not known yet. This article describes the implementation of the SIMONAL study that investigates the hypothesis of an
Autor:
Gilles Salles, Catherine Sebban, Sergei Syrbu, Alexandra Traverse-Glehan, Clémentine Sarkozy, Hervé Ghesquières, Andrew L. Feldman, George J. Weiner, William R. Macon, Brian K. Link, Cristine Allmer, Laure Lebras, Thomas M. Habermann, Emmanuelle Nicolas-Virelizier, Bertrand Coiffier, Catherine Chassagne-Clément, Stephen M. Ansell, Grzegorz S. Nowakowski, Carrie A. Thompson, David J. Inwards, Thomas E. Witzig, Emmanuel Bachy, Susan L. Slager, James R. Cerhan, Matthew J. Maurer
Publikováno v:
American Journal of Hematology. 91:1096-1101
Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall survival (OS). Here we assessed if early events as defined by event-free survival (EFS) at 12 and 24 months from diagnosis (EFS12/EFS24) can inform subsequent OS in
Autor:
Georg Maschmeyer, Bernd Metzner, Corinne Haioun, Richard Delarue, Thomas Fischer, Ulrich Dührsen, Michal Szymczyk, Jan Walewski, Mathias Hänel, Michael Unterhalt, Catherine Thieblemont, Norma Peter, Kamal Bouabdallah, Christiane Pott, Michael Hallek, Vincent Ribrag, Stephan Stilgenbauer, André Bosly, Catherine Sebban, Josef Birkmann, Christian Schmidt, Marie-Hélène Delfau-Larue, Jürgen Finke, Wolfgang Hiddemann, Nicole Brousse, Elizabeth Macintyre, Gilles Salles, Pierre Feugier, Wolfram Klapper, Roswitha Forstpointner, Eva Hoster, Michael Kneba, Rene-Olivier Casasnovas, Martin Dreyling, Lothar Kanz, Reda Bouabdallah, Olivier Hermine
Publikováno v:
Lancet
Lancet, Elsevier, 2016, 388 (10044), pp.565-75
The Lancet
The Lancet, Elsevier, 2016, 388 (10044), pp.565-575. <10.1016/S0140-6736(16)00739-X>
Lancet, Elsevier, 2016, 388 (10044), pp.565-75
The Lancet
The Lancet, Elsevier, 2016, 388 (10044), pp.565-575. <10.1016/S0140-6736(16)00739-X>
Summary Background Mantle cell lymphoma is characterised by a poor long-term prognosis. The European Mantle Cell Lymphoma Network aimed to investigate whether the introduction of high-dose cytarabine to immunochemotherapy before autologous stem-cell